Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.
作者信息
Smeenk Michiel M, van der Noort Vincent, Hendrikx Jeroen J M A, Abedian Kalkhoran Hanieh, Smit Egbert F, Theelen Willemijn S M E
机构信息
Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.
出版信息
J Immunother Cancer. 2025 Jul 22;13(7):e012095. doi: 10.1136/jitc-2025-012095.
Abstract
摘要
相似文献
1
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.对朱的《帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》评论的回应
J Immunother Cancer. 2025 Jul 22;13(7):e012095. doi: 10.1136/jitc-2025-012095.
2
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010065. doi: 10.1136/jitc-2024-010065.
3
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.对王关于“帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药——一项真实世界、回顾性双中心队列研究”的通信的回应。
J Immunother Cancer. 2025 Jul 22;13(7):e012594. doi: 10.1136/jitc-2025-012594.
4
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk .关于Smeenk的《帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》的通信
J Immunother Cancer. 2025 Jul 22;13(7):e011895. doi: 10.1136/jitc-2025-011895.
5
Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'.对“帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究”的评论
J Immunother Cancer. 2025 Mar 6;13(3):e011845. doi: 10.1136/jitc-2025-011845.
6
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
7
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.帕博利珠单抗单药治疗高程序性死亡配体1表达的晚期或转移性非小细胞肺癌的成本效益取决于长期存活者。
Clin Drug Investig. 2025 Jul 9. doi: 10.1007/s40261-025-01456-5.
8
Model-informed drug development of Mim8 - a next-generation bispecific antibody for treatment of haemophilia A.Mim8的模型指导药物研发——一种用于治疗甲型血友病的下一代双特异性抗体。
Eur J Pharm Sci. 2025 Jun 7;212:107162. doi: 10.1016/j.ejps.2025.107162.
9
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.ANV600是一种新型的靶向程序性死亡受体1（PD-1）的白细胞介素-2受体βγ激动剂，可选择性扩增肿瘤抗原特异性T细胞，并增强程序性死亡受体1（PD-1）检查点抑制剂疗法的效果。
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
10
Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer.在广泛期小细胞肺癌患者中，化疗后延迟添加PD-1/PD-L1抑制剂对治疗结果的影响。
Ther Adv Med Oncol. 2025 Jul 20;17:17588359251356919. doi: 10.1177/17588359251356919. eCollection 2025.
引用本文的文献
1
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.对王关于“帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药——一项真实世界、回顾性双中心队列研究”的通信的回应。
J Immunother Cancer. 2025 Jul 22;13(7):e012594. doi: 10.1136/jitc-2025-012594.
本文引用的文献
1
Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'.对“帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究”的评论
J Immunother Cancer. 2025 Mar 6;13(3):e011845. doi: 10.1136/jitc-2025-011845.
2
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010065. doi: 10.1136/jitc-2024-010065.
3
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.帕博利珠单抗治疗非小细胞肺癌的真实世界证据：一项全国性队列研究。
Br J Cancer. 2025 Jan;132(1):93-102. doi: 10.1038/s41416-024-02895-1. Epub 2024 Nov 3.
4
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
5
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
6
Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial.利用基于模型的“学习与确认”方法揭示帕博利珠单抗在KEYNOTE-001试验中的药代动力学-药效学关系。
CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):21-28. doi: 10.1002/psp4.12132. Epub 2016 Nov 8.
Zotero 插件